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Achilles’ heel of drug-eluting stents as compared 
with bare-metal stents, before our study, there 
was little information about the short- and long-
term comparative safety and efficacy of these 
devices for off-label indications. Our study has 
filled the short-term knowledge gap with data 
from 1 year of follow-up, and with the recent 
receipt of funding from the National Heart, 
Lung, and Blood Institute Dynamic Registry for 
continued follow-up of these patients, it is our 
goal to help fill the knowledge gap regarding 
the long-term safety and efficacy of these de-
vices.
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Reduced Exposure to Calcineurin Inhibitors  
in Renal Transplantation
To the Editor: Ekberg et al. (Dec. 20 issue)1 re-
port the results of the Efficacy Limiting Toxicity 
Elimination (ELITE)–Symphony trial, in which they 
evaluated reduced exposure to calcineurin inhib-
itors in patients undergoing renal transplantation. 
The authors’ putative conclusion is that a quadru-
ple immunosuppressive regimen of daclizumab, 
“low-dose” tacrolimus, mycophenolate mofetil, and 
corticosteroids should be considered the standard 
in renal transplantation. We have concerns, how-
ever, about the equipotency of the four immuno-
suppressive strategies used. The trough levels of 
sirolimus that were achieved in the calcineurin-
inhibitor–free group have not been demonstrated 
to be clinically effective and are, in our view, prob-
ably too low to protect grafts from acute rejection 
early after transplantation. In addition, the use of 
mammalian target of rapamycin (mTOR) inhibi-
tors such as sirolimus immediately after trans-
plantation is well known to be associated with a 
variety of acute postsurgical complications — for 
example, wound healing problems — as seen in 
this study. Therefore, most clinicians and current 
study designs strongly favor the delayed introduc-
tion of mTOR inhibitors. The high rates of side 
effects and drug discontinuation seen in the cal-
cineurin-inhibitor–free group may be due largely 
to an ill-timed early initiation of sirolimus after 
transplantation. With these study-design limita-
tions, we believe that clinicians should use caution 
when considering whether to abandon other po-
tentially valuable immunosuppressive regimens on 
the basis of the conclusions from this study.
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To the Editor: Some further issues need to be 
considered in interpreting the results of the study 
by Ekberg et al. It is well known that cyclospor-
ine, but not tacrolimus, diminishes enterohepatic 
recirculation of the major mycophenolic acid me-
tabolite, mycophenolic acid glucuronide, thereby 
resulting in a lower exposure to mycophenolic acid 
in the cyclosporine groups. Such a drug–drug in-
teraction might explain some of the results of the 
present study.1 Currently, protocols are under study 
that use a loading dose of mycophenolic acid, which 
may overcome the problem of early low exposure.
New-onset diabetes after transplantation is 
considered an important adverse effect after renal 
transplantation. Therefore, readers need to know 
how new-onset diabetes after transplantation was 
defined in the present trial. Was the definition 
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based on the American Diabetes Association–
World Health Organization guidelines as suggest-
ed in 2003?2
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To the Editor: Ekberg et al. suggest that treat-
ment with a combination of low-dose tacroli-
mus with daclizumab, mycophenolic acid, and 
corticosteroids is superior with regard to renal 
function, renal allograft survival, and acute re-
jection. However, the primary end point, the 
calculated glomerular filtration rate at month 
12, depends heavily on the completeness of the 
data. Both the group that received standard-
dose cyclosporine and the group that received 
low-dose sirolimus were at a disadvantage be-
cause of higher numbers of patients with miss-
ing values (37 and 38 patients in these two 
groups, respectively, vs. 25 and 24 in the low-
dose cyclosporine and low-dose tacrolimus 
groups, respectively, with the missing value ar-
bitrarily calculated as 10 ml per minute). Four-
teen missing calculations of the glomerular fil-
tration rate result in a mean glomerular filtration 
rate that is estimated to be 1.75 ml per minute 
lower for the whole group. Along these lines, 
when the measured glomerular filtration rate 
was used, differences between groups were 
much smaller. The authors should provide an 
explanation for this imbalance with regard to 
missing values. How would the calculated mean 
glomerular filtration rates be affected if imput-
ed values and the last observation carried for-
ward were not used for missing values?
What was the timing of the last observation 
carried forward in the different groups? What val-
ue was used for the glomerular filtration rate in 
patients who had graft loss, died, or both?
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To the Editor: On the basis of the results of the 
ELITE–Symphony study, Ekberg et al. conclude 
that a regimen containing daclizumab, mycophe-
nolate mofetil, corticosteroids, and low-dose tacro-
limus may offer an advantage over other immuno-
suppressive regimens after renal transplantation. 
However, the design of the study did not include 
a regimen containing standard-dose tacrolimus 
without daclizumab induction, whereas such a 
triple regimen is currently the standard in many 
transplantation centers. Moreover, the additional 
drug costs of about $6,500 (U.S.) incurred by the 
use of daclizumab are not discussed. Another 
strategy to reduce the adverse effects of calcineu-
rin inhibitors is to discontinue their use in im-
munologically low-risk patients. Such an approach 
has been associated with favorable long-term re-
sults1,2 and is probably more cost-effective.
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Joss N, Rodger RS, McMillan MA, Junor BJ. Randomized 
study comparing cyclosporine with azathioprine one year after 
renal transplantation — 15-year outcome data. Transplantation 
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The authors reply: The objective of the ELITE–
Symphony study was to identify a regimen of low 
toxicity and high efficacy. The choice of trough 
levels was based on commonly used long-term 
maintenance levels that we used from the day of 
transplantation and that we hypothesized to be 
equipotent. The results indicate that they were 
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not — a concern raised by Guba and Jauch; the 
sirolimus-based regimen was less effective but also 
had the highest toxicity and the greatest number 
of premature withdrawals. We concur that siroli-
mus toxicity may be reduced if its use after trans-
plantation is delayed.
Krüger and colleagues suggest that reduced 
exposure to mycophenolic acid in the cyclosporine 
group because of a drug–drug interaction may, in 
part, explain our results. We agree, but for two 
reasons we do not believe this is a major issue. 
First, although mycophenolic acid exposure is 
greater when mycophenolate mofetil is given in 
combination with sirolimus1 or tacrolimus2 than 
when it is administered with cyclosporine, the re-
sults for the sirolimus group were discordant with 
those for the tacrolimus group. Second, a larger 
proportion of patients in the tacrolimus and si-
rolimus groups received doses of mycophenolate 
mofetil that were lower than the specified dose 
(2 g per day) over the first 6-month period after 
transplantation, which would have reduced the dif-
ference in mycophenolic acid exposure between 
these groups and the cyclosporine groups. Regard-
ing the comment about new-onset diabetes after 
transplantation, our study was designed in 2002, 
when there was no established consensus defini-
tion for this condition, and before publication of 
the American Diabetes Association–World Health 
Organization guidelines. New-onset diabetes af-
ter transplantation in the ELITE–Symphony study 
was defined as adverse-event reports that included 
the term “diabetes” or “hyperglycemia.” However, 
only a small fraction of patients became insulin-
dependent.
We agree with Krämer and colleagues that the 
calculated glomerular filtration rate can be influ-
enced by the degree of completeness of the data. 
We conducted several sensitivity analyses for the 
mean glomerular filtration rate with different im-
putations and use of the last-observation-carried-
forward method. These analyses yielded the same 
pattern of results as those reported in our article, 
thus confirming the robustness of the results.
Finally, van den Hoogen and Hilbrands sug-
gest that our study should have included a triple 
regimen containing standard-dose tacrolimus 
without daclizumab induction. However, standard-
dose cyclosporine was considered the benchmark 
when our study was designed. Regarding the com-
ment about additional drug costs associated with 
daclizumab, health economics was not part of the 
scope of our article, nor were long-term changes 
in the maintenance treatment.
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Nasal CPAP for Very Preterm Infants
To the Editor: In the trial reported by Morley et 
al. (Feb. 14 issue),1 a significant reduction in the use 
of surfactant in the group treated with early con-
tinuous positive airway pressure (CPAP) as com-
pared with the intubation group (38% vs. 77%) was 
perhaps the most striking finding. In the CPAP 
group, the median time for intubation was 6.6 
hours (interquartile range, 2.2 to 19.3), and we in-
ferred from this that surfactant was probably given 
as a rescue treatment. Since the timing of surfac-
tant therapy is likely to affect outcome measures,2 
perhaps the advantages of early CPAP balanced out 
the advantages of early surfactant treatment in the 
intubation group. To address this question, a de-
tailed comparison of the timing of surfactant 
treatment in both groups would be of interest.
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